We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Emergency Approval of Ebola Test Suggests Opportunity for Test Makers

By LabMedica International staff writers
Posted on 06 Oct 2014
Print article
The emergency approval of a real-time PCR test for Zaire Ebolavirus demonstrates the scope of concern about the recent epidemic and a possible opportunity for test makers. The biennial study of the microbiology test product market, “The World Market for Infectious Disease Diagnostic Tests,” by Kalorama Information (New York City, NY, USA) estimated the world market for infectious disease tests at USD 5.3 billion in 2013 and expected it to grow at a slightly higher rate than the rest of the diagnostics market. The scourge of expanding infectious disease threats is part of the factor driving growth of tests. Partly due to the nature of the illness and the high mortality rate (often close to 90% in underdeveloped countries), Ebolavirus disease (EVD) outbreaks can get special international attention from the healthcare community.

Kalorama released its 2013 infectious disease market estimates as the United States Food and Drug Administration (FDA) announced emergency-use-authorization of a TaqMan-based test used by the Department of Defense (DOD). The test was made by the DOD, but is run on instruments from Thermo Fisher Scientific, originally from Carlsbad-based Life Technologies, bought by Thermo Fisher in February 2014. Results of the test, which analyzes blood samples, are available in about 2 hours, whereas other tests take days.

This rare type of emergency authorization by the FDA bypasses the agency's usual approval process. Usually this type of approval is issued during crises, like the current Ebola outbreak in West Africa. "Infectious disease is not an area where governments feel comfortable waiting for test results," said Bruce Carlson, publisher of Kalorama Information, "It's an opportunity for innovative technologies, and test makers who develop solutions in infectious diseases can benefit from the high priority placed on them by healthcare systems."

The Kalorama report covers standard tests for infectious disease, and has breakouts for test technologies and disease categories. Significant efforts in microbiology are detailed in company profiles.

Related Links:

Kalorama Information
The World Market for Infectious Disease Diagnostic Tests 
US FDA Emergency-Use-Authorization of test for Ebola Zaire Virus


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.